The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MEIP | -29.07% | -95.62% | -46.47% | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +524% |
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.
From the very depths of pessimism come some nice returns.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $16.46M | -15.1% |
| Market Cap / Employee | $4.11M | 0.0% |
| Employees | 4 | -85.7% |
| Net Income | -$2.69M | 85.4% |
| EBITDA | -$2.88M | 63.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.01M | 386.1% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -53.45% | -75.4% |
| Return On Invested Capital | -51.06% | 17.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.46M | 86.5% |
| Operating Free Cash Flow | -$2.46M | 86.5% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 1.95 | 1.02 | 1.09 | - | |
| Price to Book | 0.58 | 0.66 | 0.66 | 0.84 | 121.63% |
| Price to Sales | 0.53 | 0.40 | 0.30 | - | |
| Price to Tangible Book Value | 0.58 | 0.66 | 0.66 | 0.84 | 121.63% |
| Enterprise Value to EBITDA | 0.99 | 2.13 | 2.12 | 0.54 | -77.35% |
| Return on Equity | -87.7% | -93.7% | -89.7% | -63.8% | -203.50% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
